Understand the source comparison
Best Research Peptides for Androgenetic Alopecia Research: Mechanism Comparison
GHK-Cu ECM remodeling, VEGF upregulation Lysyl oxidase, TGF-β pathway 0.05–0.2% topical daily 30 days (2–8°C, light-protected) Phase II clinical data; 285% follicle enlargement in vitro TB-500 Anti-inflammatory, stem cell migration Actin, PGD2/TGF-β1 downregul
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHK-Cu
- ECM remodeling, VEGF upregulation
- Lysyl oxidase, TGF-β pathway
- 0.05–0.2% topical daily
- 30 days (2–8°C, light-protected)
- Phase II clinical data; 285% follicle enlargement in vitro
- TB-500
- Anti-inflammatory, stem cell migration
- Actin, PGD2/TGF-β1 downregulation
- 2–5mg SC twice weekly
- 28 days (2–8°C)
- Preclinical; 40–60% fibrosis reduction in wound models
- BPC-157
- Angiogenesis, NO modulation
- VEGF receptor, eNOS pathway
- 200–500mcg SC daily
- Preclinical; vascular restoration in 14–21 days
- GHK (copper-free)
- Minimal activity
- Limited without copper chelation
- Not recommended
- N/A
- Significantly reduced vs GHK-Cu
- Combination Protocol
- Multi-pathway intervention
- Inflammatory, vascular, ECM
- Stacked regimen (see text)
- Individual component limits
- Observational case series; additive effect hypothesis